ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, has announced the pre-commercial launch of its new cell analysis platform, VisionCyte—extending its product portfolio of life science research platforms beyond VisionSort, the company’s flagship product launched in 2023.

The VisionCyte platform leverages high-resolution morphological profiling, high-throughput capabilities, and advanced AI analysis to uncover novel biomarkers and facilitate the discovery of new and diversified hits and targets for drug discovery. The full commercial rollout of VisionCyte will occur in 2025, with an initial line of customer-ready units available in H2 2025.

The company also announced the launch of its Celluminate cell tracking kits, compatible with both VisionSort and VisionCyte, for enabling discovery applications in areas where existing cell surface cell markers are limited, such as specific hematological conditions, stem cell research, and age-related diseases.

“The expansion of our product portfolio reflects our unwavering commitment to advancing life science research,” said Waichiro Katsuda, CEO at ThinkCyte. “By introducing innovative solutions that address the evolving needs of scientists worldwide, we’re not just adding products—we’re providing the tools to accelerate discoveries in disease understanding and drug discovery to improve lives.”